Amuvatinib (MP-470) is primarily investigated for its potential in cancer therapy, particularly as a multi-targeted receptor tyrosine kinase inhibitor. It shows activity against several key proteins involved in tumor growth and survival, including c-Kit, PDGFR, and the DNA repair protein RAD51. By inhibiting these targets, Amuvatinib disrupts cancer cell signaling and enhances the effectiveness of DNA-damaging agents such as radiation and certain chemotherapeutics. It has been studied in combination with drugs like olaparib and temozolomide to improve responses in hard-to-treat cancers, including small cell lung cancer and glioblastoma. Its ability to suppress RAD51 makes it especially useful in impairing homologous recombination repair, a mechanism tumors often use to resist treatment. This property positions Amuvatinib as a promising radiosensitizer and chemosensitizer in oncology research. Most applications remain in the preclinical and early clinical trial stages, focusing on overcoming resistance and improving outcomes in aggressive or resistant tumor types.